Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$40.29 USD
+0.65 (1.64%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $40.39 +0.10 (0.25%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for Structure Therapeutics Inc Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 467 | 91 | 107 | -99,999 | -99,999 |
Receivables | 0 | 0 | 0 | NA | NA |
Notes Receivable | 0 | 0 | 0 | NA | NA |
Inventories | 0 | 0 | 0 | NA | NA |
Other Current Assets | 6 | 2 | 2 | NA | NA |
Total Current Assets | 474 | 93 | 109 | NA | NA |
Net Property & Equipment | 3 | 1 | 1 | NA | NA |
Investments & Advances | 0 | 0 | 0 | NA | NA |
Other Non-Current Assets | 0 | 0 | 0 | NA | NA |
Deferred Charges | 0 | 0 | 0 | NA | NA |
Intangibles | 0 | 0 | 0 | NA | NA |
Deposits & Other Assets | 0 | 3 | 0 | NA | NA |
Total Assets | 482 | 98 | 111 | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | NA | NA |
Accounts Payable | 5 | 6 | 3 | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | NA | NA |
Current Portion Capital Leases | 0 | 0 | 0 | NA | NA |
Accrued Expenses | 19 | 7 | 5 | NA | NA |
Income Taxes Payable | 0 | 0 | 0 | NA | NA |
Other Current Liabilities | 0 | 0 | 0 | NA | NA |
Total Current Liabilities | 25 | 13 | 9 | NA | NA |
Mortgages | 0 | 0 | 0 | NA | NA |
Deferred Taxes/Income | 0 | 0 | 0 | NA | NA |
Convertible Debt | 0 | 0 | 0 | NA | NA |
Long-Term Debt | 0 | 0 | 0 | NA | NA |
Non-Current Capital Leases | 0 | 0 | 0 | NA | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | NA | NA |
Total Liabilities | 29 | 13 | 9 | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 200 | 167 | NA | NA |
Common Stock (Par) | 0 | 0 | 0 | NA | NA |
Capital Surplus | 659 | 2 | 0 | NA | NA |
Retained Earnings | -207 | -117 | -65 | NA | NA |
Other Equity | 1 | 0 | 0 | NA | NA |
Treasury Stock | 0 | 0 | 0 | NA | NA |
Total Shareholder's Equity | 453 | 85 | 102 | NA | NA |
Total Liabilities & Shareholder's Equity | 482 | 98 | 111 | NA | NA |
Total Common Equity | 453 | -115 | -65 | 0 | 0 |
Shares Outstanding | 46.30 | NA | NA | NA | NA |
Book Value Per Share | 9.78 | 0.00 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for Structure Therapeutics Inc Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 927 | 436 | 467 | 205 | 225 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 11 | 13 | 6 | 5 | 4 |
Total Current Assets | 938 | 449 | 474 | 210 | 228 |
Net Property & Equipment | 3 | 3 | 3 | 2 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 0 | 0 | 0 | 0 |
Total Assets | 947 | 457 | 482 | 216 | 229 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 7 | 5 | 3 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 19 | 15 | 19 | 16 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 23 | 24 | 25 | 20 | 15 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 26 | 27 | 29 | 23 | 15 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,180 | 663 | 659 | 375 | 373 |
Retained Earnings | -259 | -233 | -207 | -182 | -158 |
Other Equity | 0 | 0 | 1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 921 | 430 | 453 | 193 | 214 |
Total Liabilities & Shareholder's Equity | 947 | 457 | 482 | 216 | 229 |
Total Common Equity | 921 | 430 | 453 | 193 | 214 |
Shares Outstanding | 46.60 | 46.60 | 46.30 | 38.20 | 38.20 |
Book Value Per Share | 19.76 | 9.22 | 9.78 | 5.05 | 5.61 |